Port Wine Stains Treatment Matrix RF Study
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of the Matrix RF for Port Wine Stains based on clinical and histological analyses.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Matrix RF followed by Pulse Dye Laser
|
Device: Matrix RF
Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
Device: Matrix RF followed by Pulse Dye Laser
Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
Device: Pulse Dye Laser followed by Matrix RF
Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
|
Outcome Measures
Primary Outcome Measures
- Time to complete healing [Up to 30 weeks]
Assess safety of the Matrix RF treatment for port wine stains
- Adverse events recording and monitoring [Up to 40 weeks]
Secondary Outcome Measures
- Clearance of port wine stain [Up to 40 weeks]
- Lightening of the port wine stain [Up to 40 weeks]
Evaluation of lightening of the port wine stain will be made with reflectance spectrophotometer at all treatments and at 6 and 12 weeks following the last treatment.
- Improvement of port wine stain [Up to 30 weeks]
Assessment to be done by the subject via subject questionnaire during these visits
- Reduction in blood vessel concentration [Up to 40 weeks]
Biopsies taken from consenting subjects at one of the time points will be analyzed
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Informed consent agreement signed by the subject.
-
Healthy males or females older than 18 to 65 years of age.
-
Having a low to mid depth Port Wine Stain of at least 5 cm2.
-
Willingness to follow the treatment and follow-up schedule and the post-treatment care.
-
For female candidates - post-menopausal or surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment and during the entire course of the study (i.e., oral contraceptives, IUD, contraceptive implant, barrier methods with spermicide, or abstinence).
Exclusion Criteria:
-
PWS on lower legs or hands.
-
Pregnant and/or breastfeeding.
-
Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
-
Having a permanent implant in the treated area, such as an injected chemical substance in the face (if treated).
-
Having a history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treated area, unless treatment is conducted following a prophylactic regimen.
-
Use of non-steroidal anti-inflammatory drugs (NSAIDS, e.g., ibuprofen-containing agents) one week before and after each treatment session.
-
Use of retinoids, antioxidants or medical grade of skin nourishing supplements within 2 months of treatment or during the study.
-
Having received a facial dermabrasion or chemical peel treatment within 3 months of treatment or during the study (if face is treated).
-
Having received treatment with light, RF or other devices in the treated area within 6 months of treatment or during the study.
-
Having received Botox/collagen/fat injections or other methods of augmentation with injected or implanted material in the treated area within 9 months of treatment or during the study (if face is treated).
-
Having undergone a resurfacing procedure, face lift or eyelid surgery within a year of treatment or during the study (if face is treated).
-
Having undergone any other surgery in the treated area within 6 months of treatment (or more if skin has not healed completely) or during the study.
-
History of keloid scarring or of abnormal wound healing.
-
Suffering from current or history of significant skin conditions in the treated area or inflammatory skin conditions, including, but not limited to: active acne, excessive skin dryness, psoriasis, eczema, rash, rosacea (particularly severe open wound stage), varicella scars, open lacerations or abrasions and active cold sores or herpes sores prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
-
History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
-
History of epidermal or dermal disorders (particularly if involving collagen or microvascularity).
-
History of pigmentary disorders, particularly tendency for hyper- or hypo-pigmentation.
-
Suffering from hormonal imbalance, as per the Investigator's discretion.
-
Having a known anticoagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
-
Having or undergoing any form of treatment for active cancer, or having a history of skin cancer or any other cancer in the areas to be treated, including actinic keratosis, presence of malignant or pre-malignant pigmented lesions.
-
Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), or pertinent neurological disorders.
-
Tattoo or permanent make-up in the treated area.
-
Excessively tanned in areas to be treated or unable/unlikely to refrain from tanning during the study.
-
Participation in a study of another device or drug within three month prior to enrollment or during the study.
-
As per the Investigator's discretion, any physical or mental condition which might make it unsafe for the subject to participate in this study.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Laser and Skin Surgery Center of New York | New York | New York | United States | 10016 |
Sponsors and Collaborators
- Syneron Medical
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DC75761